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Abstract: T-cells have a natural ability to fight cancer cells in the tumour microenvironment. Due to
thymic selection and tissue-driven immunomodulation, these cancer-fighting T-cells are generally
low in number and exhausted. One way to overcome these issues is to genetically alter T-cells to
improve their effectiveness. This process can involve introducing a receptor that has high affinity
for a tumour antigen, with two promising candidates known as chimeric-antigen receptors (CARs),
or T-cell receptors (TCRs) with high tumour specificity. This review focuses on the editing of immune
cells to introduce such novel receptors to improve immune responses to cancer. These new receptors
redirect T-cells innate killing abilities to the appropriate target on cancer cells. CARs are modified
receptors that recognise whole proteins on the surface of cancer cells. They have been shown to be
very effective in haematological malignancies but have limited documented efficacy in solid cancers.
TCRs recognise internal antigens and therefore enable targeting of a much wider range of antigens.
TCRs require major histocompatibility complex (MHC) restriction but novel TCRs may have broader
antigen recognition. Moreover, there are multiple cell types which can be used as targets to improve
the “off-the-shelf” capabilities of these genetic engineering methods.
Keywords: CAR-T; TCR-T; T-cells; cancer; immunotherapy
1. Introduction
T-cells are an important immune cell capable of recognising cancers over healthy cells. The number
of cancer specific T-cells in the body however is low, due to thymic selection. Furthermore, cancer
specific T-cells can be turned off due to tumour-expressed immunomodulatory proteins such as
PD-L1, or through dampening of the immune response due to regulatory cells [1–4]. It is possible
to overcome these issues using immune checkpoint inhibitors, ex vivo expansion and adoptive cell
therapy (ACT) with tumour-infiltrating lymphocytes (TILs) or genetically altering T-cells to improve
their effectiveness [5–7] as reviewed in [8]. While isolation and expansion of TILs from melanomas
is relatively straight forward, it is more difficult to obtain clinical efficacy in other solid cancers.
Furthermore, while TILs are enriched for tumour-specific T-cells, they still can be extremely low in
number, and adoptive transfer of TILs may result in the transfer of non-tumour reactive TILs due to
lack of in vitro enrichment. A common method to improve the response to cancer is by introducing
a receptor that has high affinity for a tumour antigen; namely chimeric-antigen receptors (CARs)
and T-cell receptors (TCRs) (forming CAR-T cells and TCR-T cells, respectively) with high tumour
specificity (Figure 1). The introduction of such receptors redirects the T-cells innate killing abilities to
the right target, in this case, the cancer cells.
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Figure 1. Production of chimeric-antigen receptor (CAR)/T-cell receptor (TCR) T-cells. T-cells are
isolated from the blood of a cancer patient. A CAR or TCR is then introduced into the isolated T-cells
through viral or non-viral delivery. CAR/TCR positive T-cells are then selected and expanded into large
numbers before being transfused back into the original cancer patient.
2. When CARs Become TRUCKs
The first CARs began as a single protein chain, where the extracellular component is formed of
an antibody able to target CD19, joined to an intracellular domain derived from the CD3ζ signalling
chain to facilitate signalling in a TCR-like manner (Figure 2) [9]. Additional engineering steps led
to second generation CARs which included a costimulatory signalling domain from CD28, or the
addition of the 4-1BB (CD137) signalling domain, resulting in a stronger signal cascade to lead to
more effective CAR-T-cells that are now the focus of clinical trials (Figure 2) [10]. Current third
generation CARs have combined these co-stimulatory signal domains (Figure 2) to further enhance
efficacy. It is also possible to design CARs to instead include a TCR construct fused to a CAR
signalling domain, which is advantageous as it allows intracellular targeting of antigens through the
major histocompatibility complex (MHC), while maintaining the potent downstream signalling of
conventional CAR constructs [11]. The main disadvantage of this type of construct is the requirement
of patient-specific MHC allele matching.
The latest iteration of CAR-T cells are known as “armoured CARs”, carrying a transgenic payload
giving them the name “T-cells Redirected for Universal Cytokine Killing” (TRUCKs) [12]. These
genetic constructs lead to the production of cytokines directly at the targeted tissue, in addition to their
direct cancer recognition (Figure 2). The pro-inflammatory cytokines, such as IL)-12, IL-2 and IL-5,
aim to attract a second wave of immune cells like natural killer (NK) cells, to clear cancer cells that may
invisible to the CAR-T [12]. Importantly, cytokines such as IL-12 have very potent pleotropic effects,
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and as such cannot be given in therapeutic doses systemically due to toxicity [13]. Therefore, targeted
accumulation at the site of disease provides a very attractive alternative.
CAR-T cells have so far been shown to be most effective in CD19 positive haematological
malignancies. Initial trials in patients showed remarkable anti-tumour reactivity in chronic lymphocytic
leukaemia (CLL) [14], acute lymphocytic leukaemia (ALL) [15] and non-Hodgkin lymphoma (NHL) [16],
using CAR-T cells targeting CD19. Indeed, patients have shown complete remission rates of 70–93% [17].
Furthermore, Tisagenlecleucel (Kymriah) is now approved to treat relapsed ALL [18], while axicabtagene
ciloleucel (Yescarta) is approved to treat relapsed diffuse large B-cell lymphoma [19].
Presently, there are 775 CAR-related clinical trials in the clinical trials database, with 66 completed
and 495 active or recruiting [20], targeting 64 different antigens [21]. The remaining 214 are not yet
recruiting, suspended, terminated, withdrawn, or unknown status. While currently only approved for
use in haematological malignancies, 33 of the 64 targets are exclusively targeting solid cancers, with an
additional 8 targeting both haematological and solid cancers. However, efficacy against solid cancers
is still unknown, so the results of these clinical trials will be invaluable. There is evidence in some solid
cancers of CAR immune infiltrations at tumour sites including a phase I/II trial with HER2-targeting
CARs in sarcoma [22], a preclinical study of WT4-targeting CARs in renal cell carcinoma [23] and
a xenogeneic model targeting glypican-1 in multiple solid tumours [24], a potential sign that CARs
may be beneficial even in some solid cancers. Indeed, the development of TRUCKs (Figure 2) is one
method to improve solid tumour efficacy, by site-directed release of cytokine in order to improve
survival of CAR TILs by changing the tumour microenvironment [25]. Solid tumour CARs may also be
improved by altering the co-stimulatory domain (Figure 2) to induce longer-lived T-cells in vivo—as
with T-cells utilising the 4-1BB domain [26]. Combination therapy of CAR-T cells with immune
checkpoint inhibitors is also being explored through various clinical trials, as reviewed in [27].
Figure 2. Generational development of chimeric antigen receptors. Chimeric antigen receptors
were first developed as extracellular single-chain variable fragments (fused light and heavy chain
from immunoglobulins) fused to the intracellular CD3ζ signalling domain. Then, 2nd generation
CARs included the CD28 or 4-1BB co-stimulatory domains, while 3rd generation CARs included
both co-stimulatory domains. The “T-cells Redirected for Universal Cytokine Killing” (TRUCKs) 4th
generation also includes a cytokine payload such as IL-12. Conventional T-cell receptors on the other
hand have signalling domains split across multiple proteins.
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3. Loss of CAR Antigen
While CARs have been proven to be very effective in multiple B-cell malignancies, there have been
cases of resistance and relapse in patients. Mechanisms of resistance include mutations in the antigenic
target resulting in loss of recognition by the CAR-T cell, mostly due to the truncation of the protein and
therefore loss of surface expression of the antigen [28]. One unique case of remission occurred when a
single malignant B-cell was accidently transduced with the CAR, enabling cis binding of the expressed
CAR to the CD19 antigen, masking the CD19 epitope to CAR-T cells and therefore resistance to the
CAR therapy [29]. To overcome mechanisms of resistance, it is possible to target a secondary molecule,
such as CD22 or CD20 which are also often expressed on B-cell malignancies [30–32]. This can be done
concurrently with anti-CD19 CARs, or as a secondary treatment post-relapse [33]. Indeed, one 8-year
old patient received sequential treatments of anti-CD19 CAR, followed by anti-CD22 CAR resulting
in partial response, subsequently followed by anti-CD20 CAR which cleared the cancer to complete
remission [34]. Rather than giving each of these treatments sequentially, a recent CAR construct was
designed to transduce donor T-cells with CD19, CD20 and CD22 targeting CARs in the same cell [35],
thus cells that lose expression of one of the lineage markers would still be cleared by the adoptively
transferred CARs.
It is also possible to introduce a CAR specific to a Fcγ-receptor (FcγR), enabling restriction of CARs
to an FcγR tagged tumour-targeting antibody [36,37]. This is advantageous over conventional CAR-T
cells as the specificity of the CAR can be changed simply by changing the antibody. Furthermore,
multiple tumour-targeting antibodies can be used at the same time, enabling the CAR-T cell to
target multiple tumour antigens. FcγR CAR-T-cells can also have their toxicities managed through
removal of the tumour targeting antibody, mitigating the effects of cytokine release syndrome (CRS).
A similar methodology can be employed with an affinity-enhanced monomeric streptavidin 2 (mSA2)
biotin-binding domain able to bind to biotin-tagged antibodies, enabling modular targeting of cancers
that bind the antibody [38].
4. TCR-T, the Place to Be?
While CARs target surface tumour antigens with an antibody-like moiety, major histocompatibility
complex restricted antigens offer a source of antigens that are both intracellular and secreted.
This greatly increases the potential range of targets that can be recognised by genetically altered T-cells.
One method being explored targets MHC-presented peptides using a CAR, for example recognition of
α-fetoprotein peptide bound to human leukocyte antigen (HLA)-A0201 [39]. α-fetoprotein is a known
cancer-associated protein but is only expressed intracellularly or secreted making it undruggable from
the perspective of conventional CARs. Therefore, using the feature of MHC presentation, this has
become a viable line of research. Furthermore, as TCRs are natural receptors for peptide-MHC, these
remain ready to be exploited in the form of the introduction of a cancer-specific TCR into the peripheral
T-cell pool analogous to CARs. Regarding antigens for these TCRs to target, there are generally two types
of peptides: Those arising from mutations that differ from wild type antigens (that are not recognised
by the immune system through self-tolerance mechanisms) known as neo-antigens, and those that
result from over-expression or aberrantly expressed genes—known as tumour-associated antigens
(TAA). Regarding the former, many avenues of research are now focusing on such a personalised
treatment, due to the requirement of matching the TCR to the correct HLA, in addition to identification
of cancer-specific mutations.
There are multiple ways to identify neo-antigens, and the TCRs that recognise them. One common
way is through sequencing of a patient’s cancer cells to identify cancer-specific mutations that can be
targeted, which are processed through an MHC-binding prediction to enrich the antigens for those that
are more likely to be presented to T-cells [40], test these using HLA-tetramers [41], finally identifying
TCRs that target these antigens through clonal T-cell analyses or single cell sequencing [42–44]. TCR-T
cells can then be synthesised and adoptively transferred to the patient. This of course greatly increases
the lead time therapy; however, it is potentially advantageous in that the TCR-T have confirmed
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reactivity to the tumour and will be 100% matched to the patient HLA. Neoantigens-reactive T-cells
are also appealing as they are specific to cancer mutations and, therefore, less likely to react to
non-cancerous somatic cells.
On the other hand, it is possible to target shared antigens across cancer and patients, which
is advantageous over neoantigen reactive TCRs as TAA are often shared between individuals and
between different cancers. As TAA often arise from proteins that are not usually expressed somatically
in adults, they remain viable targets for TCR-T therapy. To use one case as an example, TCR-T cells
engineered to target the common melanoma TAA NY-ESO-1 have been produced [45]. The responses
to this TCR-T have been encouraging, with clinical benefit seen in 80% of patients.
A further opportunity to develop broad, population wide TCR-T cells is to use HLA-agnostic TCRs.
This overcomes the issue of patient-specific unique MHC alleles that restrict their tumour antigens.
Indeed, an exciting new avenue of research is to use the recently discovered MR1-restricted TCR known
as MC.7.G5 [46]. This TCR recognises cancer regardless of tissue origin, and as MR1 is monomorphic
in the population, this TCR has potential to be used as an “off-the-shelf” TCR that can be used in many
patients without the caveat of MHC-restriction, analogous to CAR-T-cells. Importantly, while this TCR
showed the killing of both autologous and non-autologous cancer cells when the TCR was transferred
to the T-cells of a cancer patient, it remained inert to healthy cells, demonstrating its potential in cancer
treatment. Other non-MHC-restricted TCRs also exist, such as anti-cancer γδ TCRs, which when
transduced to donor T-cells have been shown to redirect non-cancer specific T-cells to kill cancer cells
through recognition of metabolites of the mevalonate pathway that is upregulated in cancers [47].
There are also additional αβ TCRs that are not restricted by MHC but other invariant molecules, such
as CD1c [48], offering further opportunities to explore TCR-T cells using these unconventional T-cells.
A potential source of neoantigen, TAA and HLA-agnostic reactive TCRs are in the tumour
microenvironment itself; it has been well documented that tumour-infiltrating lymphocytes are
enriched for tumour-reactive T-cells [44,49–51], as evidenced by the success of TIL-based cancer
immunotherapy. As TILs are often exhausted and may have limited in vivo proliferative ability once
transferred back into the patient [52,53], genetically engineering T-cells with a more naïve phenotype
could increase the activatory potential, compared to unedited TILs. Furthermore, use of TCR-T cells
over CAR-T cells has the advantage of the potential for epitope spreading, where T-cells with different
antigen specificities to the adoptively transferred targeted antigen are also activated [54].
5. Examples of TCR-T
TCR-T cell therapies have been slower to reach clinical approval states for treatment of cancers.
However, there have been studies that show the effectiveness of such treatments, leading to over
70 clinical trials involving TCR-T therapy (Table 1) [20]. These numbers indicate a real interest in
moving forward with TCR-T as a viable therapy. One promising TCR-T target is the NY-ESO-1c125 TCR
targeting a NY-ESO-1/LAGE-1a derived peptide presented on HLA-A2, in patients with metastatic
synovial sarcoma [55]. Anti-tumour responses were seen in 50% of patients, which is commendable
considering metastatic synovial sarcoma is a solid cancer that is incurable with standard therapy.
Furthermore, NY-ESO-1c125 T-cells persisted for at least 6 months in responders and showed effector
memory phenotypes. NY-ESO-1 targeting TCR-T cells have also been shown to be effective in both
melanoma and synovial sarcoma, with 3-year survival rates of 33% and 38%, respectively [56].
T-cells have also been engineered to express a TCR targeting the melanoma associated antigen
gp100, together with a CAR targeting CSPG4 antigen, which has shown in vitro cytokine release and
cytotoxicity [57]. These multi-target TCR-T cells have yet to be tested in animal models or humans,
however. Interestingly, using multiple targets on the same cell could be exploited in the use of “logic
gates”—whereby signalling domains are split across two or even three receptors, so only cells that
possess both receptor targets activate the T-cell [58].
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Table 1. Clinical trials involving TCR-T therapy.
Cancer Type Target MHC Clinical trialNumber Status Year Notes
Cervical Intraepithelial HPV E7 HLA-A*02:01 NCT04411134 Phase I - Not yetrecruiting 2020
Soft Tissue Sarcoma NY-ESO-1 HLA-A*02:01 NCT04318964 Phase I - Recruiting 2020 Affinity enhanced TCR
Unresectable
Hepatocellular Carcinoma AFP HLA-A 02:01 NCT04368182 Phase I - Recruiting 2020
Solid tumour Tumour antigens N/A NCT03891706 Phase I - Recruiting 2019 Screen for tumourreactivity and clone TCRs
Oropharyngeal squamous
cell carcinoma HPV E7 HLA-A*02:01 NCT04044950
Phase II - Not yet
recruiting 2019
Oesophagus, Hepatoma,
Glioma, Gastric
NY-ESO-1,
Mesothelin, EGFRvIII
and DR5
HLAA*0201 NCT03941626 Phase I/II - Recruiting 2019
CAR-T/TCR-T cells include
four different
tumour-specific antibodies
HPV-Associated
Oropharyngeal HPV E7 HLA-A 02:01 NCT04015336 Phase II - Recruiting 2019
Solid Tumour Autologous tumourantigen N/A NCT03970382 Phase I - Recruiting 2019
2 arms - with and without
anti-PD-1 antibody
Vulvar High-Grade
Squamous Intraepithelial HPV E7 HLA-A*0201 NCT03937791 Phase II - Recruiting 2019
Head and Neck Squamous
Cell Carcinoma HPV-16 E6 - NCT04139057 Phase I/II - Recruiting 2019
anti-PD1 auto-secreted
element
Human Papillomavirus
(HPV) 16+
Relapsed/Refractory
HPV E7 HLA-A*02:01 NCT03912831 Phase I - Recruiting 2019
Nasopharyngeal Carcinoma LMP2 HLA-A2, HLA-A11or HLA-A24 NCT03925896 Phase I - Recruiting 2019
Glioma, glioblastoma - - NCT03392545 Phase I - Recruiting 2019
High Grade Squamous
Intraepithelial HPV E6 HLA-A*02:01 NCT03197025 Phase I - Completed 2019
A single patient, no
response
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Table 1. Cont.
Cancer Type Target MHC Clinical trialNumber Status Year Notes
Pancreatic KRAS G12V Mutant HLA-C*08:02 NCT04146298 Phase I/II - Recruiting 2019 Anti-PD1 adjuvant ifrequired
Breast Autologous tumourantigen - NCT04194190
Individual Patient
Expanded Access 2019
Single patient individual
access
Prostate TP53 - NCT04135092 Individual PatientExpanded Access 2019
Single Patient Expanded
Access
Hepatocellular Carcinoma AFP HLA-A 02:01 NCT03971747 Phase I - Recruiting 2019
Non-small cell lung Tumour antigens N/A NCT03778814 Phase I - Recruiting 2018 Screen for tumourreactivity and clone TCRs
Cervical Cancer, Head and
Neck Squamous Cell
Carcinoma
HPV-E6 Not provided NCT03578406 Phase I - Recruiting 2018 TCR-T secretion ofanti-PD1
Wide range of solid and
liquid cancers
CD19, CD22, CD33,
CD38, BCMA,
NY-ESO-1, c-met,
Mesothelin,
CEGFRvIII and DR5
HLA-A*0201 NCT03638206 Phase I/II - Recruiting 2018
Colorectal TGFβRII frameshiftantigen HLA-A*0201 NCT03431311
Phase I/II -
Terminated 2018
Only 1 patient enrolled, no
results given
Fallopian Tube Carcinoma,
Ovarian carcinoma,
peritoneal carcinoma
NY-ESO-1 HLA- A*02.1 andHLA-DP*04 NCT03691376 Phase I - Recruiting 2018
Melphalan
pre-conditioning and TCR+
HSC transfer in addition to
CD8+ TCR+ cells
Nasopharyngeal Carcinoma LMP1, LMP2 andEBNA1 HLA-A*0201/2402/1101 NCT03648697
Phase II - Not yet
recruiting 2018
Bone Sarcoma, Soft Tissue
Sarcoma NY-ESO-1 HLA-A*02:01 NCT03462316 Phase I - Recruiting 2018
Solid cancers Patient-specificmutations N/A NCT03412877 Phase II - Recruiting 2018
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Table 1. Cont.
Cancer Type Target MHC Clinical trialNumber Status Year Notes
Gastrointestinal, Pancreatic,
Gastric, Colon, Rectal
G12D Variant of
Mutated RAS HLA-A*11:01 NCT03745326 Phase I/II - Recruiting 2018 Murine TCR.
Myeloid and Lymphoid
Neoplasms
Preferentially
Expressed Antigen in
Melanoma (PRAME)
HLA-A*0201 NCT03503968 Phase I/II - Recruiting 2018
Broad NY-ESO-1/ LAGE-1a
HLA-A*02:01,
HLA-A*02:05,
and/or
HLA-A*02:06
NCT03709706 Phase II - Recruiting 2018 Includes a pembrolizumabcombination treatment arm
Merkel Cell Cancer Merkel cellpolyomavirus HLA-A*02:01 NCT03747484 Phase I/II - Recruiting 2018
Inclusion requires previous
anti-PD1 treatment
Lung Cancer, Non-small
Cell, Recurrent NY-ESO-1 HLA-A*0201 NCT03029273 Phase I - Recruiting 2017 Affinity enhanced TCR
Acute Leukaemia HA-1 HLA-A*0201+ NCT03326921 Phase I - Recruiting 2017
Relapsed or refractory
patients after stem cell
transplant
Vaginal, Cervical, Anal,
Penile, Oropharyngeal HPV-16 E6 HLA-A*02:01 NCT02280811 Phase I/II - Completed 2017
Partial response in 2/12
treated patients
Clear Cell Renal Cell
Carcinoma HERV-E HLA-A*11:01 NCT03354390 Phase I - Recruiting 2017
HERV-E is an endogenous
retrovirus
Solid tumour MAGE-A3/A6 HLA-DPB1*04:01 NCT03139370 Phase I - Recruiting 2017
Gastrointestinal, Pancreatic,
Gastric, Colon, Rectal
G12V Variant of
Mutated RAS HLA-A*11:01 NCT03190941 Phase I/II - Recruiting 2017 Murine TCR.
Synovial Sarcoma NY-ESO-1 (HLA)-A*02:01 orHLA-A*02:06 NCT03250325
Phase I/II - Active, not
recruiting 2017
Cervical Intraepithelial
Neoplasia, Carcinoma in
Situ, Vulvar
HPV E7 HLA-A*02:01 NCT02858310 Phase I/II - Recruiting 2016
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Table 1. Cont.
Cancer Type Target MHC Clinical trialNumber Status Year Notes
Recurrent Hepatocellular
Carcinoma Hepatitis B Not given NCT02719782 Phase I - Recruiting 2016
Hepatocellular Carcinoma Hepatitis B Not given NCT02686372 Phase I - Recruiting 2016
Haematological Cytomegalovirus(CMV) HLA-A*0201 NCT02988258 Phase I - Suspended 2016
Suspended (Protocol being
re-written to allow
inclusion of more patients)
Multiple NY-ESO-1 HLA-A*0201 NCT02775292 Phase I - Completed 2016
Also included NY-ESO-1
pulsed Dendritic cells
adoptively transferred
Multiple NY-ESO-1 HLA-A*0201 NCT02774291 Phase I - Recruiting 2016 Uses murine TCR
Melanoma MART-1 HLA-A*0201 NCT02654821 Phase I/II - Active, notrecruiting 2016
Multiple NY-ESO-1 HLA-A*0201 NCT02650986 Phase I/II - Recruiting 2016
Also included TGFbDNRII
gene. Two treatment arms,
one included chemotherapy
drug decitabine
Metastatic NY-ESO-1 HLA-A*0201 NCT02062359 Phase II - Terminated 2016
Study was closed due to
poor accrual. TCR
transduced into CD62L+
cells.
Melanoma tyrosinase HLA-A2 NCT02870244 Phase I - Recruiting 2016
Acute Myeloid Leukaemia Wilms tumour [WT]1 HLA-A*0201 NCT02770820 Phase I/II - Active, notrecruiting 2016
Myelodysplastic
Syndromes (MDS)Acute
Myeloid Leukaemia (AML)
WT1 HLA-A*02:01 NCT02550535 Phase I/II - Completed 2015 No results posted
Multiple NY ESO-1 HLA-A*02:01 NCT02457650 Phase I - Unknown 2015
Verified August 2016 by
Shenzhen Second People’s
Hospital. Recruitment
status was: Recruiting
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Table 1. Cont.
Cancer Type Target MHC Clinical trialNumber Status Year Notes
Thyroid Cancer Thyroglobulin HLA-A*0201 NCT02390739 Phase I/II -Withdrawn 2015 No results posted
Solid NY-ESO-1 HLA-A*0201 NCT02366546 Phase I - Active, notrecruiting 2015
Non-small Cell Lung
Cancer or Mesothelioma WT1 HLA-A*0201 NCT02408016
Phase I/II - Active, not
recruiting 2015
Solid MAGE-A4 HLA-A*24:02 NCT02096614 Phase I - Unknown 2014
Verified November 2017 by
Shinichi Kageyama, Mie
University. Recruitment
status was: Recruiting
Breast, Cervical, Renal,
Melanoma, Bladder MAGE-A3 HLA-A 01 NCT02153905
Phase I/II -
Terminated 2014
Terminated due to slow,
insufficient accrual. 1/3
Patients had PR
Unidentified solid tumour NY-ESO-1 HLA-A*0201 NCT02070406 Phase I - Terminated 2014
Including DC vaccine and
ipilumab treatment.
Terminated due to low
accrual.
Melanoma, Meningioma,
Breast, Non-Small Cell
Lung, Hepatocellular
NY-ESO-1 HLA-A*0201 NCT01967823 Phase II - Completed 2013 No results posted
Metastatic MAGE-A3/12 HLA-A*0201 NCT01273181 Phase I/II -Terminated 2013 4/9 Patients had CR or PR
AML and CML WT1 HLA-A*0201 NCT01621724 Phase I/II - Completed 2012 Completed, no resultsposted
Multiple NY-ESO-1 HLA-A*0201 NCT01697527 Phase II - Active, notrecruiting 2012
Ovarian NYESO-1c259
HLA A*0201,
HLA-A*0205,
and/or HLA-A*0206
NCT01567891 Phase I/II - Completed 2012 0/6 responses
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Table 1. Cont.
Cancer Type Target MHC Clinical trialNumber Status Year Notes
Melanoma tyrosinase HLA-A2 NCT01586403 Phase I - Active, notrecruiting 2012
Melanoma gp 100:154, MART-1F5 HLA-A*0201 NCT00923195 Phase II - Completed 2012
Also, peptide vaccines.
Progressive disease in 4/4
patients.
Leukaemia WT1 HLA-A*0201 NCT01640301 Phase I/II - Active, notrecruiting 2012 After allogeneic HCT
Melanoma NY-ESO-1c259 HLA-A*0201 NCT01350401
Phase I/II -
Terminated 2011
Terminated due to lack of
enrolment.
Melanoma TP53 HLA-A*0201 NCT00393029 Phase II - Completed 2011 1/9 Patients had tumourregression
Multiple Myeloma NY-ESO-1c259 HLA-A*0201 NCT01352286 Phase II - Completed 2011 OS of 35.1.
Renal, Kidney
TNF-related
apoptosis inducing
ligand (TRAIL)
HLA-DR4 NCT00923390 Phase I/II -Terminated 2009
Terminated after 10 years,
no results posted
Kidney, Melanoma,
Unspecified Adult Solid
Tumour
TP53 HLA-A*0201 NCT00704938 Phase II - Terminated 2008
Includes adenovirus p53
dendritic cell (DC) vaccine.
Terminated due to
withdrawal of support from
collaborator. No CR or PR.
Melanoma MART-1 F5 HLA-A*0201 NCT00706992 Phase II - Terminated 2008
<11 subjects were enrolled
to each Arm. No immune
responses observed.
Information sourced from 20.
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6. TCR-T Limitations
A confounding factor of TCR-based genetic engineering is the issue of TCR chain cross pairing.
This is due to the fact TCRs exist as heterodimers and introduced TCR-α chains can pair with the
endogenous TCR-β and vice versa. This is potentially hazardous as these mis-paired TCRs could
harbour harmful neoreactivities [59]. There are however multiple methods to overcome mispairing
issues. TCRs can be generated into a single chain CAR-like construct to prevent cross pairing, however
such a construct can result in 10–100× less sensitivity for their cognate antigen [60]. However another
study found the use of only the variable region of the beta chain which resulted in no loss of TCR
sensitivity [61]. It is also possible to introduce a novel TCR while simultaneously knocking out the
endogenous TCR. This can be achieved in two ways; either through co-transfer of a CRISPR lentivirus
targeting the endogenous TCR-β chain [47] or through targeting the TCR gene insertion at both the
TCR-α and TCR-β locus resulting in direct TCR gene replacement, allowing physiological expression
of the engineered TCR [62]. The latter is achieved through non-viral delivery of DNA and therefore,
arguably, reduces the time and expense associated with viral-based delivery of genes. The added
benefit of knocking out the endogenous TCR is reduced competition for TCR co-receptors such as
CD3 [63]. In a recent clinical trial, T-cells engineered with an NY-ESO-1 targeting TCR in addition to
CRISPR knockout of both the endogenous TCR and PD-1, with edited T-cell detectable nine months
post-transfusion, indicating viability of CRISPR edited, tumour-specific engineered TCR-T cells [64].
7. Target Cells
An exciting avenue of research is to introduce cancer-reactive TCRs using αβ-TCRs into γδ T-cells;
as γδ T-cells express a different TCR isoform they cannot mis-pair introduced TCRs with endogenous.
This is further advantageous in that γδ T-cells have been shown to have some natural anticancer
reactivity [43,65–67] in addition to a range of other features not known to conventional αβ T-cells, such
as antigen presentation [68].
Another potential target cell line for both CAR- and TCR-constructs is NK cells; as they do not
possess an endogenous TCR there is no possibility of cross pairing of TCR chains. Furthermore, NK
cells are able to both directly kill cells and secrete cytokines. There are some concerns that NK cells
are poor at homing to cancer sites, but this may be overcome by using more advanced TRUCKs.
As an example, one group has shown editing NK cells to express CD19-reactive CARs along with
the IL-15 gene and a suicide gene could effectively clear xenograft B-cell leukaemia or lymphoma in
mice models [69]. Indeed, NK-CARs have also shown efficacy in humans, with 7 out of 11 patients
achieving complete remission with no development of severe adverse events such as CRS [70]. These
NK-CARs expanded and persisted for at least 12 months, however other NK cell-based ACT studies
have often failed to detect the presence of infused NK cells no more than a couple of weeks after
infusion [71–73]. Macrophages have also recently been used to generate CAR-Ms, demonstrating
antigen-specific phagocytosis and tumour clearance in vitro, with the added benefit of direct antigen
presentation and cytokine secretion [74]. CAR-Ms persisted for at least 62 days in this immune deficient
NSG mouse model, however it is difficult to assess the persistence in human cancer patients.
8. When to Turn Engineered Cells On and Off
Both CAR-T and TCR-T show promise but can also have side effects; notably cytokine release
syndrome and immune effector cell-associated neurotoxicity syndrome (ICANS). Currently, these are
treated with steroids or anti-IL-6 therapy [75], however this could diminish the overall immune response.
An additional caveat with engineered T-cells is on-target off-tumour specific toxicity. This occurs
when a cancer target is expressed on tissues other than the cancer. An example showing this is in
the case of CD133-directed CAR-T cells, as while CD133 is expressed on some leukaemia cells, it is
also expressed on haemopoietic stem and progenitor cells, potentially causing severe toxicity [76].
Off-target, off-tumour toxicities can also occur, as evidenced with the MAGE-A3 TCR-T that resulted
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in severe cardiotoxicity and death of two patients due to TCR cross-reactivity to an antigen from
Titin—which is only expressed on beating cardiomyocytes [39,40]. This study was important to show
how potent TCR-T cells can be in vivo, but also highlight the importance of rigorous pre-clinical testing.
There are efforts to mitigate these side-effects from the genetic construct. One method is to
introduce suicide switches into the edited cells—where an administered drug at a designated interval
induces cell death of only the edited cells. This can be achieved through inclusion of druggable targets
such as inducible caspase-9 which leads to CAR-T cell apoptosis upon administration of a small
molecule [69]. Such suicide genes prevent some of the toxicities associated with over-stimulation of
CAR-T-cells [75]. It is also possible to include the aforementioned logic gates [21,31].
9. Concluding Remarks
Cancer immunotherapy is now a vital part of the therapy regimen for cancer treatment.
With CAR-T-cells showing outstanding results in B-cell malignancies, there is scope to expand
the number of targets and nuances of the therapy to improve outcomes further. Particularly, design of
novel CARs to target multiple antigens concurrently represents a promising line of research, such as
larger CAR constructs so individual cells can target multiple antigens, or in the case of separate CAR-T
cells adoptively transferred simultaneously. The introduction of CARs to include payloads such as
cytokine secretion may also provide more potent efficacy. A major caveat with CAR therapy is cytokine
release syndrome due to the high affinity antigen targeting—this can be mitigated through addition of
cellular switches [21], logic gates [31] or through decoupling of direct antigen targeting through the use
of FcγR CARs alongside infusion of tumour-targeting antibodies [38]. This enables removal of antigen
target, or dose escalation in a much more controlled manner than in direct CAR-target recognition.
Unfortunately, the evidence of effective CAR-T-cell therapy in solid tumours remains limited.
While some studies have shown effects in some solid tumours, there is still more research to be done.
Indeed, there is difficulty in finding solid tumour antigens due to the lack of lineage specific markers
as in the case of CD19/20/22 targeting CARs. As TCRs offer targeting of tumour specific neoantigens,
use of TCR-T cell could be utilised for more specific solid tumour targets. The main caveat associated
with TCR-T therapy is the requirement of MHC restriction, requiring identification of patient specific
antigen receptors in contrast to the broad targets of CARs. However, there are example cases of TCRs
targeting common HLA alleles such NY-ESO-1 mutated antigens on HLA-A0201 [77], or TCR targeting
ubiquitous molecules such as tumour-associated MR1 [46].
Changing the recognition target of T-cells is not the only mechanism of gene editing in T-cells.
As TILs are already a viable treatment option in solid cancers, particularly melanoma, it is feasible to
try to improve responses in treatment resistant patient. It is possible, for example, to use CRISPR to
knockout T-cell exhaustion markers that may be regulating the activity of adoptively transferred T-cells;
examples of which include PD-1 knockout [78,79], DGK) knockout to increase TCR activation [80],
or pooled gene knock-ins to improve in vivo T-cell fitness [81]. Finally, there is recent evidence of
the development of universal CAR-T-cells, where CD52 was knocked out in CAR-T cells, to prevent
graft-versus-host disease by preventing CAR-T-cell loss upon anti-CD52 mediated depletion of immune
cells during therapy [82]. Such, off-the-shelf treatments greatly reduce cost and lead-time to treatment,
paving the way for adoption of treatment as standard of care.
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